Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 995

1.

Environmental arginine controls multinuclear giant cell metabolism and formation.

Brunner JS, Vulliard L, Hofmann M, Kieler M, Lercher A, Vogel A, Russier M, Brüggenthies JB, Kerndl M, Saferding V, Niederreiter B, Junza A, Frauenstein A, Scholtysek C, Mikami Y, Klavins K, Krönke G, Bergthaler A, O'Shea JJ, Weichhart T, Meissner F, Smolen JS, Cheng P, Yanes O, Menche J, Murray PJ, Sharif O, Blüml S, Schabbauer G.

Nat Commun. 2020 Jan 22;11(1):431. doi: 10.1038/s41467-020-14285-1.

2.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jan 22. pii: annrheumdis-2019-216655. doi: 10.1136/annrheumdis-2019-216655. [Epub ahead of print]

PMID:
31969328
3.

Comparing the patient reported physical function outcome measures in a real-life international cohort of patients with psoriatic arthritis.

Leung YY, Orbai AM, de Wit M, Balanescu A, Dernis E, Soubrier M, Eder L, Smolen JS, Coates LC, Gossec L; ReFlap Study Group.

Arthritis Care Res (Hoboken). 2020 Jan 21. doi: 10.1002/acr.24139. [Epub ahead of print]

PMID:
31961492
4.

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.

Smolen JS, Choe JY, Weinblatt ME, Emery P, Keystone E, Genovese MC, Myung G, Hong E, Baek I, Ghil J.

RMD Open. 2020 Jan;6(1). pii: e001096. doi: 10.1136/rmdopen-2019-001096.

5.

Treatment to Target in Psoriatic Arthritis with Apremilast: Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.

Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A, Mcinnes I, Queiro R, Guerette B, Brunori M, Teng L, Smolen JS.

Arthritis Care Res (Hoboken). 2020 Jan 7. doi: 10.1002/acr.24134. [Epub ahead of print]

PMID:
31909868
6.

Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis.

Göschl L, Preglej T, Boucheron N, Saferding V, Müller L, Platzer A, Hirahara K, Shih HY, Backlund J, Matthias P, Niederreiter B, Hladik A, Kugler M, Gualdoni GA, Scheinecker C, Knapp S, Seiser C, Holmdahl R, Tillmann K, Plasenzotti R, Podesser B, Aletaha D, Smolen JS, Karonitsch T, Steiner G, Ellmeier W, Bonelli M.

J Autoimmun. 2019 Dec 26:102379. doi: 10.1016/j.jaut.2019.102379. [Epub ahead of print]

PMID:
31883829
7.

Greetings from the editor 2020.

Smolen JS.

Ann Rheum Dis. 2020 Jan;79(1):1-2. doi: 10.1136/annrheumdis-2019-216758. No abstract available.

PMID:
31843989
8.

An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases.

Vanier A, Smolen JS, Allaart CF, Vollenhoven RV, Verschueren P, Vastesaeger N, Saevarsdottir S, Visser K, Aletaha D, Combe B, Fautrel B.

Rheumatology (Oxford). 2019 Nov 13. pii: kez542. doi: 10.1093/rheumatology/kez542. [Epub ahead of print]

PMID:
31722413
9.

Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.

Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL.

Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9.

10.

Preface.

Breedveld FC, Kalden JR, Smolen JS.

Semin Arthritis Rheum. 2019 Dec;49(3S):S1-S2. doi: 10.1016/j.semarthrit.2019.10.004. Epub 2019 Oct 31. No abstract available.

PMID:
31706626
11.

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.

Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R.

RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019.

12.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.

Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, Bykerk V, Dougados M, Rosenbaum JT, Mariette X, Sieper J, Melchers F, Cronstein BN, Breedveld FC, Kalden J, Smolen JS, Furst D.

Ann Rheum Dis. 2020 Jan;79(1):88-93. doi: 10.1136/annrheumdis-2019-216151. Epub 2019 Oct 29. Review.

13.

Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association with Gender in 458 Patients from 14 Countries.

Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, Palominos PE, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin S, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L.

Arthritis Care Res (Hoboken). 2019 Oct 14. doi: 10.1002/acr.24090. [Epub ahead of print]

PMID:
31609525
14.

Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.

Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS.

Semin Arthritis Rheum. 2019 Sep 19. pii: S0049-0172(19)30286-0. doi: 10.1016/j.semarthrit.2019.09.005. [Epub ahead of print]

PMID:
31590930
15.

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis.

Kroon F, Bay-Jensen AC, Wittoek R, Verbruggen G, Smolen JS, Kloppenburg M, Ramonda R.

Scand J Rheumatol. 2019 Sep 30:1-2. doi: 10.1080/03009742.2019.1657493. [Epub ahead of print] No abstract available.

PMID:
31566063
16.

Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary.

Smolen JS.

Rheum Dis Clin North Am. 2019 Nov;45(4):477-485. doi: 10.1016/j.rdc.2019.07.001. Epub 2019 Aug 16. Review.

PMID:
31564291
17.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group.

Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28.

18.

Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening.

Böhler C, Weimann P, Alasti F, Smolen JS, Windhager R, Aletaha D.

Semin Arthritis Rheum. 2019 Aug 1. pii: S0049-0172(19)30374-9. doi: 10.1016/j.semarthrit.2019.07.011. [Epub ahead of print]

PMID:
31471012
19.

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.

Aletaha D, Maa JF, Chen S, Park SH, Nicholls D, Florentinus S, Furtner D, Smolen JS.

Ann Rheum Dis. 2019 Dec;78(12):1609-1615. doi: 10.1136/annrheumdis-2018-214918. Epub 2019 Aug 21.

20.

Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets.

Aletaha D, Smolen JS.

Nat Rev Rheumatol. 2019 Nov;15(11):633-634. doi: 10.1038/s41584-019-0279-6. No abstract available.

PMID:
31427763
21.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
22.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

23.

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns.

Platzer A, Nussbaumer T, Karonitsch T, Smolen JS, Aletaha D.

PLoS One. 2019 Jul 25;14(7):e0219698. doi: 10.1371/journal.pone.0219698. eCollection 2019.

24.

IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs.

Bonelli M, Dalwigk K, Platzer A, Olmos Calvo I, Hayer S, Niederreiter B, Holinka J, Sevelda F, Pap T, Steiner G, Superti-Furga G, Smolen JS, Kiener HP, Karonitsch T.

Exp Mol Med. 2019 Jul 8;51(7):75. doi: 10.1038/s12276-019-0267-6.

25.

Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?

Aletaha D, Smolen JS.

Rheum Dis Clin North Am. 2019 Aug;45(3):315-324. doi: 10.1016/j.rdc.2019.04.002. Epub 2019 Jun 5. Review.

PMID:
31277746
26.

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.

Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P.

Arthritis Res Ther. 2019 Jul 5;21(1):164. doi: 10.1186/s13075-019-1937-4.

27.

MicroRNA-155 Controls T Helper Cell Activation During Viral Infection.

Goncalves-Alves E, Saferding V, Schliehe C, Benson R, Kurowska-Stolarska M, Brunner JS, Puchner A, Podesser BK, Smolen JS, Redlich K, Bonelli M, Brewer J, Bergthaler A, Steiner G, Blüml S.

Front Immunol. 2019 Jun 13;10:1367. doi: 10.3389/fimmu.2019.01367. eCollection 2019.

28.

Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.

Smolen JS, Pedersen R, Jones H, Mahgoub E, Marshall L.

Rheumatology (Oxford). 2020 Jan 1;59(1):153-164. doi: 10.1093/rheumatology/kez224.

PMID:
31257453
29.

Era of biosimilars in rheumatology: reshaping the healthcare environment.

Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY.

RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900. eCollection 2019. Review.

30.

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.

Michaud K, Pope JE, Emery P, Zhu B, Gaich CL, DeLozier AM, Zhang X, Dickson CL, Smolen JS.

Rheumatol Ther. 2019 Sep;6(3):409-419. doi: 10.1007/s40744-019-0164-4. Epub 2019 Jun 21.

31.

Disease activity assessment in patients with psoriatic arthritis.

Kerschbaumer A, Smolen JS, Aletaha D.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):401-414. doi: 10.1016/j.berh.2018.08.004. Epub 2018 Oct 11. Review.

PMID:
31171311
32.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.

Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S.

Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23. Erratum in: Lancet. 2019 Jun 29;393(10191):2590.

33.

Greetings from the editor.

Smolen JS.

Ann Rheum Dis. 2019 Jun;78(6):715. doi: 10.1136/annrheumdis-2019-215621. No abstract available.

PMID:
31088798
34.

Multimodal [18 F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice.

Hayer S, Zeilinger M, Weiss V, Dumanic M, Seibt M, Niederreiter B, Shvets T, Pichler F, Wadsak W, Podesser BK, Helbich TH, Hacker M, Smolen JS, Redlich K, Mitterhauser M.

J Bone Miner Res. 2019 Sep;34(9):1632-1645. doi: 10.1002/jbmr.3748. Epub 2019 Jul 30.

35.

Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study.

Leiss H, Hucke M, Bécède M, Machold-Fabrizii V, Smolen JS, Machold KP.

Sci Rep. 2019 Apr 10;9(1):5867. doi: 10.1038/s41598-019-42387-4.

36.

Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA.

Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):783-790. Epub 2019 Apr 9.

37.

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT.

Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.

PMID:
30926722
38.

An intergenerational program based on psycho-motor activity promotes well-being and interaction between preschool children and older adults: results of a process and outcome evaluation study in Austria.

Mosor E, Waldherr K, Kjeken I, Omara M, Ritschl V, Pinter-Theiss V, Smolen J, Hübel U, Stamm T.

BMC Public Health. 2019 Mar 1;19(1):254. doi: 10.1186/s12889-019-6572-0.

39.

Risk profiling for a refractory course of rheumatoid arthritis.

Bécède M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, Loiskandl M, Supp GM, Smolen JS, Aletaha D.

Semin Arthritis Rheum. 2019 Oct;49(2):211-217. doi: 10.1016/j.semarthrit.2019.02.004. Epub 2019 Feb 8.

40.

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.

Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, Tanaka Y.

Mod Rheumatol. 2020 Jan;30(1):36-43. doi: 10.1080/14397595.2019.1583711. Epub 2019 Mar 21.

PMID:
30784354
41.

Challenges and strategies for hypertension management: qualitative analysis of small primary care practices with varying blood pressure control.

Smolen JR, Wang JJ, Anane SP.

Fam Pract. 2019 Oct 8;36(5):644-649. doi: 10.1093/fampra/cmz004.

PMID:
30753404
42.

Achieving Clinical Remission for Patients With Rheumatoid Arthritis.

Aletaha D, Smolen JS.

JAMA. 2019 Feb 5;321(5):457-458. doi: 10.1001/jama.2018.21249. No abstract available.

PMID:
30721278
43.

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.

Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, Nurwakagari P, Weinman J.

RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585. eCollection 2019.

44.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
45.

I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis.

Mosor E, Stoffer-Marx M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, Skingle D, Dobrin M, Schett G, Englbrecht M, Smolen JS, Kjeken I, Hueber AJ, Stamm TA.

Arthritis Care Res (Hoboken). 2019 Feb 2. doi: 10.1002/acr.23841. [Epub ahead of print]

PMID:
30710453
46.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

47.

FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes.

Brandstetter B, Dalwigk K, Platzer A, Niederreiter B, Kartnig F, Fischer A, Vladimer GI, Byrne RA, Sevelda F, Holinka J, Pap T, Steiner G, Superti-Furga G, Smolen JS, Kiener HP, Karonitsch T.

Lab Invest. 2019 May;99(5):648-658. doi: 10.1038/s41374-018-0184-7. Epub 2019 Jan 24.

PMID:
30679758
48.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Sep;46(9):1159-1163. doi: 10.3899/jrheum.181081. Epub 2019 Jan 15.

PMID:
30647174
49.

Greetings from the editor 2019.

Smolen JS.

Ann Rheum Dis. 2019 Jan;78(1):1-2. doi: 10.1136/annrheumdis-2018-214822. No abstract available.

PMID:
30563867
50.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156

Supplemental Content

Loading ...
Support Center